본문 바로가기
KERD
논문KCI 등재

알츠하이머병 뇌척수액 생물표지자 다기관 연구를 위한 예비연구

Preliminary Study for a Multicenter Study of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers

김태은|김윤정|나덕렬|이동현|최성혜|서상원|김형준|박정호|김종헌|임수재|채원석|박선아
대한치매학회 (Korean Dementia Association)|2013.03|Dementia and Neurocognitive Disorders(대한치매학회지) (Dementia and Neurocognitive Disorders)|제12권 제1호|pp. 1-8|DOI http://dx.doi.org/10.12779/dnd.2013.12.1.1

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

Alzheimer’s diseaseBiomarkerTauEnzyme-linked immunosorbent assayCerebrospinal fluidAmyloid beta protein
주제분류신경과학

초록

Background: The usefulness of cerebrospinal fluid (CSF) concentrations of amyloid beta protein 1-42(Aβ42), phosphorylated tau (pTau) and total tau (tTau) have been increasing in Alzheimer’s disease (AD). However, the direct adoption of previously reported standard values is not appropriate due to interlaboratory variability. We started this study to set up an accessible system to measure CSF biomarkers in our country with high reproducibility and validity. Methods: Including CSFs from four different institutes the levels of Aβ42, pTau181 and tTau were measured in one lab. The intertest variability and difference in the levels of biomarkers depending on diseases were assessed. Through analysis of receiver operating characteristic cut points and binary logistic regression the cut-off values of Aβ42, pTau and tTau level were obtained, and their validity was evaluated. Results: The intertest consistency was high in measuring CSF biomarkers. The value of Aβ42 was markedly decreased in AD (n= 17) and other dementia (n= 9) compared to normal control (n= 12). The levels of pTau181 and tTau were high in AD, but not in other dementia and normal control. The threshold values of Aβ42, pTau181 and tTau were 290.3 pg/mL, 54.3 pg/mL, and 320.7 pg/mL in differentiating AD from normal control showing high sensitivity and specificity. Especially, the ratios of pTau181/Aβ42 (> 0.16) and tTau/Aβ42 (> 0.76) showed the prime validity. Conclusions:Our data of CSF Aβ42, pTau181, and tTau levels were highly reproducible. PTau181/Aβ42 and tTau/Aβ42 ratios were the greatly helpful in differentiating AD from normal control.

Abstract

Background: The usefulness of cerebrospinal fluid (CSF) concentrations of amyloid beta protein 1-42(Aβ42), phosphorylated tau (pTau) and total tau (tTau) have been increasing in Alzheimer’s disease (AD). However, the direct adoption of previously reported standard values is not appropriate due to interlaboratory variability. We started this study to set up an accessible system to measure CSF biomarkers in our country with high reproducibility and validity. Methods: Including CSFs from four different institutes the levels of Aβ42, pTau181 and tTau were measured in one lab. The intertest variability and difference in the levels of biomarkers depending on diseases were assessed. Through analysis of receiver operating characteristic cut points and binary logistic regression the cut-off values of Aβ42, pTau and tTau level were obtained, and their validity was evaluated. Results: The intertest consistency was high in measuring CSF biomarkers. The value of Aβ42 was markedly decreased in AD (n= 17) and other dementia (n= 9) compared to normal control (n= 12). The levels of pTau181 and tTau were high in AD, but not in other dementia and normal control. The threshold values of Aβ42, pTau181 and tTau were 290.3 pg/mL, 54.3 pg/mL, and 320.7 pg/mL in differentiating AD from normal control showing high sensitivity and specificity. Especially, the ratios of pTau181/Aβ42 (> 0.16) and tTau/Aβ42 (> 0.76) showed the prime validity. Conclusions:Our data of CSF Aβ42, pTau181, and tTau levels were highly reproducible. PTau181/Aβ42 and tTau/Aβ42 ratios were the greatly helpful in differentiating AD from normal control.

참고문헌 (45)

  1. Asien PS, "Report of the task force on designing clinical trials in early (pre dementia) AD", Neurol, 76, pp.280~286 (2011)
  2. Golde TE, "Anti-aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift", Neuron, 69, pp.203~213 (2011)
  3. Cummings JL, "Biomarkers in Alzheimer’s disease drug development", Alzheimers Dement, 7, pp.e13~e44 (2011)
  4. Mueller SG, "Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s disease Neuroimaging Initiative (ADNI)", Alzheimers Dement, 1, pp.55~66 (2005)
  5. Choi J, "Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer’s disease", J Neurol, 258, pp.2181~2185 (2011)
  6. Han SH, "Human serum transthyretin levels correlate inversely with Alzheimer’s disease", J Alzheimers Dis, 25, pp.77~84 (2011)
  7. Kim SM, "Identification of peripheral inflammatory markers between normal control and Alzheimer’s disease", BMC Neurol, 11, pp.51~ (2011)
  8. Lee KS, "Bioplex analysis of plasma cytokines in Alzheimer’s disease and mild cognitive impairment", Immunol Lett, 121, pp.105~109 (2008)
  9. Lee JW, "Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer’s disease", BMC Neurol, 7, pp.14~ (2007)
  10. Holtzman DM, "CSF biomarkers for Alzheimer’s disease: current utility and potential future use", Neurobiol Aging, 32, pp.S4~S9 (2011)
  11. Zetterberg H, "Amyloid beta and APP as biomarkers for Alzheimer’s disease", Exp Gerontol, 45, pp.23~29 (2010)
  12. Blennow K, "CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease", Mol Neurobiol, 24, pp.87~97 (2001)
  13. Buerger K, "Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231", Arch Neurol, 59, pp.1267~1272 (2002)
  14. Shaw LM, "Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects", Ann Neurol, 65, pp.403~413 (2009)
  15. Welge V, "Combined CSF tau, p-tau181 and amyloid-beta 38", 40, J Neural Transm, pp.2009, 116[DOI]
  16. 이은희, "한국의 알츠하이머병 환자에서 아세틸콜린 에스터레이스 억제제의 뇌척수액 베타아밀로이드 1-42 분획과 인산화타우단백 농도에 미치는 효과", 대한신경과학회지, 26(3), pp.224~230 (2008), 대한신경과학회
  17. McKhann G, "Clinical diagnosis of Alzheimer’s disease—report of the NINCDSADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease", Neurology, 34, pp.939~944 (1984)
  18. Dubois B, "Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria", Lancet Neurol, 6, pp.734~746 (2007)
  19. Emre M, "Clinical diagnostic criteria for dementia associated with Parkinson’s disease", Mov Disord, 22, pp.1689~1707 (2007)
  20. McKeith IG, "Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium", Neurology, 65, pp.1863~1872 (2005)
  21. Neary D, "Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria", Neurology, 51, pp.1546~1554 (1998)
  22. Litvan I, "Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop", Neurology, 47, pp.1~9 (1996)
  23. Roman GC, "Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS-AIREN international workshop", Neurology, 43, pp.250~260 (1993)
  24. Bjerke M, "Confounding factors influencing amyloid beta concentration in cerebrospinal fluid", Int J Alzheimers Dis, 2010, pp.986310~ (2010)
  25. Bateman RJ, "Fluctuations of CSF amyloid- β levels: Implications for a diagnostic and therapeutic biomarker", Neurology, 68, pp.666~669 (2007)
  26. Verwey NA, "A wordwide multicenter comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease", Ann Clin Biochem, 46, pp.235~240 (2009)
  27. Schoonenboom NS, "Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort", Neurology, 78, pp.47~54 (2012)
  28. Kemmppainen NM, "Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease", Ann Neurol, 63, pp.112~118 (2008)
  29. Motter R, "Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease", Ann Neurol, 38, pp.643~648 (1995)
  30. Sunderland T, "Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease", JAMA, 289, pp.2094~2103 (2003)
  31. Fagan AM, "Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans", Ann Neurol, 59, pp.512~519 (2006)
  32. Fagan AM, "Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease", EMBO Mol Med, 1, pp.371~380 (2009)
  33. Weigand SD, "Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid", Alzheimers Dementia, 7, pp.133~141 (2011)
  34. Englund H, "Oligomerization partially explains the lowering of Abeta42 in Alzheimer’s disease cerebrospinal fluid", Neurodegener Dis, 6, pp.139~147 (2009)
  35. Hampel H, "Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study", Arch Gen Psychiatry, 61, pp.95~102 (2004)
  36. Hu YY, "Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay", Am J Pathol, 160, pp.1269~1278 (2002)
  37. Vemuri P, "MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change", Neurology, 73, pp.294~301 (2009)
  38. Vemuri P, "Serial MRI and CSF biomarkers in normal aging, MCI, and AD", Neurology, 75, pp.143~151 (2010)
  39. Montine TJ, "CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment", Mov Disord, 25, pp.2682~2685 (2010)
  40. Rowe CC, "Imaging beta-amyloid burden in aging and dementia", Neurology, 68, pp.1718~1725 (2007)
  41. Lee JH, "Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B", Neurology, 77, pp.18~25 (2011)
  42. Galasko D, "Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease", Neurology, 48, pp.632~635 (1997)
  43. Hulstaert F, "Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF", Neurology, 52, pp.1555~1562 (1999)
  44. Andreasen N, "Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample", Neurology, 53, pp.1488~1494 (1999)
  45. Riemenschneider M, "Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration", Neurology, 58, pp.1622~1628 (2002)

관련 논문AI추천

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease강은숙, 강주희, 기창석, 김상윤, 김성윤, 노지훈, 박선아, 윤영철대한신경과학회 · Journal of Clinical Neurology2015 · 제11권 제2호뇌척수액과 말초혈액 내 알츠하이머병의 생화학적 생체표지자김어수, 박민선, 이영민, 최원정대한노인정신의학회 · 노인정신의학2012 · 제16권 제1호The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer’s Disease Biomarkers박선아, 채원석, Ho Sik Shin, Hyung-Jun Kim, Saeromi Kim, Seung-Keun Lee대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2016 · 제15권 제4호Cerebrospinal Biomarker Cut-off Methods Defined Only by Alzheimer’s Disease Predict More Precisely Conversions of Mild Cognitive Impairment김규식, 김종헌, 이준홍, 이지언, 임현선, 조정희, 최성혜, Alzheimer’s Disease Neuroimaging Initiative대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2017 · 제16권 제4호Efficacy of the Phosphorylated tau 181 in Differential Diagnosis of the Alzheimer’s Disease - A Systematic Review and Meta-Analysis이민, 김희진, 모진아, 설아람, 윤영철, 임주희, 장재원대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2014 · 제13권 제4호한국의 알츠하이머병 환자에서 아세틸콜린 에스터레이스 억제제의 뇌척수액 베타아밀로이드 1-42 분획과 인산화타우단백 농도에 미치는 효과권오상, 민주홍, 박광열, 윤영철, 이은희, 이현옥, 홍현종대한신경과학회 · 대한신경과학회지2008 · 제26권 제3호

이 간행물의 다른 논문 (3건)

Neurologists’ Awareness and Preparedness on Prion Diseases in Korea김상윤, 박영호, 임재성, 박수철, 정해관, 김정은, 장재원pp. 9-20A Semi-Automated Method for Measuring White Matter Hyperintensity Volume심용수, 양동원, 윤보라, 홍윤정, 조아현pp. 21-28Serial Changes in Diffusion-Weighted Magnetic Resonance Images with Hypoperfusion on Brain SPECT in a Case of Hashimoto’s Encephalopathy: Understanding Pathophysiology of Hashimoto’s Encephalopathy박경원, 김성재, 정은환, 박미경, 최순섭pp. 29-32
원문 보기